Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023)

Historic EBT Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' EBT Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063875218800.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • According to the latest figures from Q4 2023, Inhibikase Therapeutics' EBT Margin is 440356600.0%, which was down 4403497803600.0% from 5993.38% recorded in Q3 2023.
  • In the past 5 years, Inhibikase Therapeutics' EBT Margin registered a high of 187.4% during Q1 2021, and its lowest value of 440356600.0% during Q4 2023.
  • Moreover, its 4-year median value for EBT Margin was 5660.72% (2023), whereas its average is 27549285.01%.
  • Per our database at Business Quant, Inhibikase Therapeutics' EBT Margin soared by 2000000000bps in 2022 and then plummeted by 2000000000bps in 2023.
  • Quarter analysis of 4 years shows Inhibikase Therapeutics' EBT Margin stood at 708.85% in 2020, then tumbled by -36487bps to 259342.54% in 2021, then soared by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Its EBT Margin was 440356600.0% in Q4 2023, compared to 5993.38% in Q3 2023 and 5328.07% in Q2 2023.